Cellectar Biosciences, Inc.
CLRB · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $26,136 | $27,266 | $19,220 | $17,586 |
| G&A Expenses | $25,641 | $11,694 | $9,594 | $6,545 |
| SG&A Expenses | $25,641 | $11,694 | $9,594 | $6,545 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $51,778 | $38,961 | $28,814 | $24,131 |
| Operating Income | -$51,778 | -$38,961 | -$28,814 | -$24,131 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $7,262 | -$3,870 | -$3,039 | $9 |
| Pre-Tax Income | -$44,515 | -$42,831 | -$31,853 | -$24,122 |
| Tax Expense | $66 | -$60 | -$60 | $0 |
| Net Income | -$44,581 | -$42,771 | -$31,793 | -$24,122 |
| % Margin | – | – | – | – |
| EPS | -36.52 | -104.988 | -135.179 | -130.353 |
| % Growth | 65.2% | 22.3% | -3.7% | – |
| EPS Diluted | -41.89 | -104.988 | -135.179 | -130.353 |
| Weighted Avg Shares Out | 1,221 | 407 | 235 | 185 |
| Weighted Avg Shares Out Dil | 1,238 | 407 | 235 | 185 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1,211 | $387 | $153 | $2 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $292 | $192 | $148 | $150 |
| EBITDA | -$51,486 | -$38,768 | -$28,665 | -$23,981 |
| % Margin | – | – | – | – |